The Latest
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
Roche and Dianthus Therapeutics licensed cancer and immune drugs, respectively, in two deals collectively worth up to nearly $2.5 billion.
Updated Oct. 17, 2025 -
DMP via Getty Images
Sponsored by LabcorpMaximizing biomarker insights from minimal samples
Unlock value with optimized workflows and scalable technologies.
-
Getty Images
News roundupI-Mab morphs into ‘hub-and-spoke’ biotech; Astellas passes on Taysha gene therapy
I-Mab is rebranding as a company that will form individual drugmaking subsidiaries. Elsewhere, Sanofi cut an immune drug deal and investors poured $140 million into a new hair loss treatment.
-
Getty Images
J&J claims success in study testing earlier Tecvayli use in multiple myeloma
The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to later-line settings for the persistent blood cancer.
-
Courtesy of Novartis
Novartis confirms drug’s benefits in rare kidney disease as competitors loom
The findings position Fabhalta to secure a standard approval in IgA nephropathy — a crowded area of drug research — at a time when newer types of medicines are quickly advancing.
-
Courtesy of Novo Nordisk
Novo wagers up to $2.1B on Omeros’ rare disease drug
The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called complement-mediated diseases.
-
Scott Olson via Getty Images
Obesity drugsLilly, battling skepticism, reinforces GLP-1 pill’s case with new study data
Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials.
-
Getty Images
California passes laws targeting PBMs, private equity
Gov. Gavin Newsom signed an array of healthcare bills into law last week that crack down on pharmacy benefit managers and beef up the review process for deals involving private equity firms.
-
Getty Images
Emerging biotechCancer drug startup Tubulis raises $361 million for ADCs
The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer drug that’s being showcased at a medical meeting on Sunday.
-
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
6 drug startups have raised more than $1.5 billion combined this week, continuing an upturn in venture funding that began in September.
Updated Oct. 15, 2025 -
Getty Images
Obesity drugsKailera nets $600M more to advance Zepbound-like obesity drug
Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.
-
Getty Images
Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy
Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a dozen children with a rare, genetic form of deafness.
-
Getty Images
BioCryst goes ‘all in’ on rare swelling disease with Astria deal
A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema that complements its daily pill.
-
Getty Images
News roundup
AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance
AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, Novo is shuttering its cell therapy division and an investor wants Novavax to sell itself.
-
Permission granted by Excellergy
Startup launchesA young biotech nets $70M for a new type of allergy drug
Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company says could lead to faster and more complete disease control.
-
Courtesy of Johnson & Johnson
J&J plans to spin out orthopedics business
CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such as cardiovascular and robotics.
-
Getty Images
Immune resetBristol’s $1.5B Orbital buyout extends ‘in vivo’ cell therapy deal streak
The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body.
-
Getty Images
Trump administration moves to fire HHS employees amid shutdown
“HHS employees across multiple divisions have received reduction-in-force notices,” an administration spokesperson confirmed. It’s a significant escalation of normal shutdown procedures.
-
Getty Images
Novo joins MASH dealmaking surge with $4.7B Akero buyout
The deal is the third acquisition since May involving a drug that could reverse liver scarring in people with metabolic dysfunction-associated steatohepatitis.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech’s M&A outlook is uncertain. Track the deals that are happening here.
BioCryst is acquiring Astria Therapeutics in a cash-and-stock deal that gives the company a long-acting preventive therapy for the rare disease hereditary angioedema.
Updated Oct. 14, 2025 -
Getty Images
News roundup
AstraZeneca ups investment in Virginia; Moderna vets launch VC fund
The British pharma is adding $500 million, and ADC production capabilities, to a planned Virginia facility. Elsewhere, Ferring announced layoffs and Sanofi touted a radiopharmaceutical drug.
-
Getty Images
IPO windowEvommune files for IPO to advance immune drug work
The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for chronic skin hives.
-
Adeline Kon/BioPharma Dive
Deep Dive // Emerging biotechBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Evommune on Thursday outlined plans for an offering that would support development of two drugs in mid-stage testing for urticarias and atopic dermatitis.
Updated Oct. 9, 2025 -
Courtesy of Regeneron Pharmaceuticals
Regeneron, needing a turnaround, gains new use for cancer drug
Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the “broad-reaching implications” for Regeneron's Eylea franchise investors had hoped.
-
Getty Images
Startup launchesVenture firms pour $101M into a biotech using the brain to fix the immune system
Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by targeting a special kind of nerve cell.
-
Bhagavatheeshwaran, Govind. (2016). "MRI Scan" [Image]. Retrieved from Flickr.
China competitionZenas looks to China to stock pipeline with 3 more immune drugs
A potentially $2 billion deal with InnoCare Pharma hands Zenas rights to a BTK inhibitor in late-stage testing for multiple sclerosis and two other immune medicines in earlier development.
